Company news

Ovid Therapeutics Inc. news in 2021

Ovid Therapeutics Inc.'s news releases, calls and decks from 2021, newest first.

View company

Ovid Therapeutics Reports Third Quarter 2021 Business Update, Corporate Highlights and Financial Results

November 9, 2021

Ovid Therapeutics Appoints Dr. Kevin Fitzgerald to Board of Directors

October 6, 2021

Ovid Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

September 6, 2021

Ovid Therapeutics Reports Second Quarter 2021 Financial Results and Corporate Highlights

August 15, 2021

Ovid Therapeutics Strengthens Board & Leadership Team to Focus Efforts on Expanding Its Neurosciences Capabilities

July 7, 2021

Ovid Therapeutics to Present at the Ladenburg Thalmann 2021 Healthcare Conference

July 6, 2021

Ovid Therapeutics Appoints Jeff Rona as Chief Business and Financial Officer

June 3, 2021

Ovid Therapeutics Appoints Dr. Joy A. Cavagnaro and Dr. Bruce A. Sullenger to its Scientific Advisory Board

May 25, 2021

Ovid Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update

May 12, 2021

Ovid Therapeutics to Participate in the 2021 RBC Capital Markets Global Healthcare Conference

May 11, 2021

Ovid Therapeutics Announces Appointment of Professor Robert S. Langer, Sc.D., as Chair of its Scientific Advisory Board

April 19, 2021

OVID Provides Update on OV101 Program and the Prioritization of its Resources

April 18, 2021

Ovid Therapeutics Announces Closing of Agreement with Takeda for Global Development and Commercialization of Soticlestat

March 29, 2021

Ovid Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results, Provides Corporate Update for 2021

March 14, 2021

Takeda Secures Global Rights from Ovid Therapeutics to Develop and Commercialize Soticlestat for the Treatment of Children and Adults with Dravet Syndrome and Lennox-Gastaut Syndrome

March 2, 2021

Decks in 2021